About
About
Philosophy
Culture
Transparency
Leadership Team
Partners
Sustainability
Innovation
Innovation
Investigator Research
Educational Grants
Clinical Trial Data Privacy Policy
Medical Writing Grants
Medical Information
News
News
News Posts
Media Assets
Products
Investors
Careers
Contact
United States
Worldwide
HOME
News
News
Back number
Please select
2022
2021
2020
2019
2018
2017
2016
2015
2014
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
August
Aug.11, 2022
Release
Ensitrelvir Fumaric Acid (S-217622), a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.2.75
July
Jul.14, 2022
Release
S-217622, a Therapeutic Drug for COVID-19, Shows High In Vitro Antiviral Activity Against Omicron Subvariants BA.4 And BA.5
Jul.01, 2022
Release
Notice Regarding the Launch of the new SHIONOGI Group Brand
June
Jun.14, 2022
Release
Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements To Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries
Jun.01, 2022
Release
Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership
April
Apr.23, 2022
Release
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
March
Mar.16, 2022
Release
ACTG and Shionogi Announce Progress on Global Phase 3 Trial of Novel COVID-19 Oral Antiviral Agent S 217622
Mar.11, 2022
Release
Shionogi Provides Humanitarian Aid to Ukraine
February
Feb.25, 2022
Release
Shionogi Files for Approval of S-217622, a Therapeutic Drug for COVID-19, in Japan
Feb.18, 2022
Release
Shionogi Presents Phase 2/3 Clinical Trial Results (Phase 2a Part) for the COVID-19 Therapeutic Drug S-217622